600436 Stock Overview
Zhangzhou Pientzehuang Pharmaceutical., Ltd engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally.
No risks detected for 600436 from our risk checks.
Zhangzhou Pientzehuang Pharmaceutical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||CN¥252.69|
|52 Week High||CN¥486.15|
|52 Week Low||CN¥250.22|
|1 Month Change||-14.05%|
|3 Month Change||-28.42%|
|1 Year Change||-25.60%|
|3 Year Change||149.89%|
|5 Year Change||333.73%|
|Change since IPO||7,502.35%|
Recent News & Updates
|600436||CN Pharmaceuticals||CN Market|
Return vs Industry: 600436 underperformed the CN Pharmaceuticals industry which returned -24.5% over the past year.
Return vs Market: 600436 underperformed the CN Market which returned -18.6% over the past year.
|600436 Average Weekly Movement||3.5%|
|Pharmaceuticals Industry Average Movement||4.7%|
|Market Average Movement||5.8%|
|10% most volatile stocks in CN Market||9.3%|
|10% least volatile stocks in CN Market||3.7%|
Stable Share Price: 600436 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 3% a week.
Volatility Over Time: 600436's weekly volatility (3%) has been stable over the past year.
About the Company
|n/a||2,591||Jin Ming Huang||https://www.zzpzh.com.cn|
Zhangzhou Pientzehuang Pharmaceutical., Ltd engages in the manufacture and sale of Chinese medicines under the Pien Tze Huang brand in China and internationally. The company’s products include medicines and health products, cosmetics, daily chemicals, medical apparatus and instruments, and health foods. The company is based in Zhangzhou, China.
Zhangzhou Pientzehuang Pharmaceutical Fundamentals Summary
|600436 fundamental statistics|
Is 600436 overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|600436 income statement (TTM)|
|Cost of Revenue||CN¥4.35b|
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
|Earnings per share (EPS)||4.36|
|Net Profit Margin||30.60%|
How did 600436 perform over the long term?See historical performance and comparison
0.5%Current Dividend Yield
Is 600436 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 600436?
Other financial metrics that can be useful for relative valuation.
|What is 600436's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does 600436's PE Ratio compare to its peers?
|600436 PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
600276 Jiangsu Hengrui Medicine
000538 Yunnan Baiyao GroupLtd
600196 Shanghai Fosun Pharmaceutical (Group)
000661 Changchun High-Tech Industries (Group)
600436 Zhangzhou Pientzehuang Pharmaceutical
Price-To-Earnings vs Peers: 600436 is expensive based on its Price-To-Earnings Ratio (58x) compared to the peer average (31.8x).
Price to Earnings Ratio vs Industry
How does 600436's PE Ratio compare vs other companies in the CN Pharmaceuticals Industry?
Price-To-Earnings vs Industry: 600436 is expensive based on its Price-To-Earnings Ratio (58x) compared to the CN Pharmaceuticals industry average (29.4x)
Price to Earnings Ratio vs Fair Ratio
What is 600436's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||58x|
|Fair PE Ratio||35.1x|
Price-To-Earnings vs Fair Ratio: 600436 is expensive based on its Price-To-Earnings Ratio (58x) compared to the estimated Fair Price-To-Earnings Ratio (35.1x).
Share Price vs Fair Value
What is the Fair Price of 600436 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 600436 (CN¥252.69) is trading below our estimate of fair value (CN¥319.38)
Significantly Below Fair Value: 600436 is trading below fair value by more than 20%.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.
Discover undervalued companies
How is Zhangzhou Pientzehuang Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 7 analysts?
Future Growth Score3/6
Future Growth Score 3/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 600436's forecast earnings growth (21.4% per year) is above the savings rate (3.2%).
Earnings vs Market: 600436's earnings (21.4% per year) are forecast to grow slower than the CN market (25.8% per year).
High Growth Earnings: 600436's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 600436's revenue (16.5% per year) is forecast to grow slower than the CN market (18.2% per year).
High Growth Revenue: 600436's revenue (16.5% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 600436's Return on Equity is forecast to be high in 3 years time (24.2%)
Discover growth companies
How has Zhangzhou Pientzehuang Pharmaceutical performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 600436 has high quality earnings.
Growing Profit Margin: 600436's current net profit margins (30.6%) are higher than last year (27%).
Past Earnings Growth Analysis
Earnings Trend: 600436's earnings have grown significantly by 25.1% per year over the past 5 years.
Accelerating Growth: 600436's earnings growth over the past year (36.9%) exceeds its 5-year average (25.1% per year).
Earnings vs Industry: 600436 earnings growth over the past year (36.9%) exceeded the Pharmaceuticals industry 6%.
Return on Equity
High ROE: 600436's Return on Equity (25%) is considered high.
Discover strong past performing companies
How is Zhangzhou Pientzehuang Pharmaceutical's financial position?
Financial Health Score6/6
Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: 600436's short term assets (CN¥11.7B) exceed its short term liabilities (CN¥2.6B).
Long Term Liabilities: 600436's short term assets (CN¥11.7B) exceed its long term liabilities (CN¥213.1M).
Debt to Equity History and Analysis
Debt Level: 600436 has more cash than its total debt.
Reducing Debt: 600436's debt to equity ratio has reduced from 9.4% to 7.4% over the past 5 years.
Debt Coverage: 600436's debt is well covered by operating cash flow (698.1%).
Interest Coverage: 600436 earns more interest than it pays, so coverage of interest payments is not a concern.
Discover healthy companies
What is Zhangzhou Pientzehuang Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Score 4/6
Cash Flow Coverage
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 600436's dividend (0.48%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.52%).
High Dividend: 600436's dividend (0.48%) is low compared to the top 25% of dividend payers in the CN market (2.1%).
Stability and Growth of Payments
Stable Dividend: 600436's dividends per share have been stable in the past 10 years.
Growing Dividend: 600436's dividend payments have increased over the past 10 years.
Earnings Payout to Shareholders
Earnings Coverage: With its reasonably low payout ratio (27.8%), 600436's dividend payments are well covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: With its low cash payout ratio (13.5%), 600436's dividend payments are thoroughly covered by cash flows.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Jin Ming Huang (56 yo)
Mr. Jin Ming Huang is GM & Director of Zhangzhou Pientzehuang Pharmaceutical., Ltd from July 2019. He joined the Zhangzhou Pientzehuang Pharmaceutical., Ltd in September 2006. Mr. Huang served as President...
Experienced Management: 600436's management team is considered experienced (3.2 years average tenure).
Experienced Board: 600436's board of directors are considered experienced (3.2 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Zhangzhou Pientzehuang Pharmaceutical., Ltd's employee growth, exchange listings and data sources
- Name: Zhangzhou Pientzehuang Pharmaceutical., Ltd
- Ticker: 600436
- Exchange: SHSE
- Founded: NaN
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: CN¥152.452b
- Shares outstanding: 603.32m
- Website: https://www.zzpzh.com.cn
Number of Employees
- Zhangzhou Pientzehuang Pharmaceutical., Ltd
- Pien Tze Huang Building
- 1st Floor
- Fujian Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|600436||SHSE (Shanghai Stock Exchange)||Yes||Domestic Shares||CN||CNY||Jun 2003|
|600436||XSSC (Shanghai Stock Exchange - Shanghai - Hong Kong Stock Connect)||Yes||Domestic Shares||CN||CNY||Jun 2003|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/25 00:00|
|End of Day Share Price||2022/09/23 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.